Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Heart Failure, Heart Failure With Reduced Ejection Fraction

In brief

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Key facts

Study ID

NCT06736574

Run by

Cytokinetics

People needed

1800

Starts

2024-12-19

Expected to finish

2027-12-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients who meet all the following criteria at screening may be included in the study:
• Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
• Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
• Are receiving oral loop diuretics on a regular schedule
• Patients without AFF on screening ECG:
• LVEF < 30% within 6 months of screening
• Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 1000 pg/mL (BNP ≥ 300 pg/mL)
• Patients with AFF on screening ECG:
• LVEF < 25% within 6 months of screening
• Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 3000 pg/mL (BNP ≥ 900 pg/mL)
• Not currently taking digoxin
• Meet one of the following criteria for a recent HF event:
• Are currently hospitalized with the primary reason of HF
• Had an HF event (as defined in the primary endpoint) within 12 months prior to screening. For the purposes of a qualifying HF event, subcutaneous furosemide will be treated as equivalent to intravenous furosemide Or
• Had outpatient escalation of oral diuretics due to worsening signs and symptoms of heart failure plus one of two additional criteria sustained for at least 1 week: (1) at least 50% or 1.5-fold increase in daily loop-diuretic-equivalent dose; (2) the addition of a new diuretic class to a loop diuretic.
• Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
• Systolic blood pressure ≤ 140 mmHg

You may not qualify if…

• Any of the following criteria will exclude potential patients from the study:
• Have AFF on the screening ECG and are currently taking digoxin
• Have had any event or procedure that may have resulted in a change in ejection fraction, including, but not limited to, acute coronary syndrome and/or any coronary revascularization, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization, or cardiac contractility modulation therapy within 3 months of screening
• Are admitted to a long-term care facility or hospice
• Have a projected survival of < 12 months due to non-cardiovascular causes based on clinical judgment
• Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
• Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
• Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening (except for nocturnal supplemental oxygen for sleep apnea or heart failure)
• Have an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2 or receiving dialysis at screening
• Have previously had a solid organ transplant
• Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
• Have received omecamtiv mecarbil in a previous clinical trial
• Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP
• Have primary infiltrative cardiomyopathy (e.g. cardiac amyloidosis) or severe stenotic valvular disease

Where it is running

• Sutter Institute for Medical Research (SIMR) — Sacramento, California, United States (enrolling)
• UC Davis Health — Sacramento, California, United States (enrolling)
• San Diego Cardiac Center — San Diego, California, United States (enrolling)
• California Pacific Medical Center Van Ness Campus — San Francisco, California, United States (enrolling)
• Kaiser Permanente Santa Clara — Santa Clara, California, United States (enrolling)
• Stanford University Hospital / Stanford Health Care — Stanford, California, United States (enrolling)
• Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center — Torrance, California, United States (enrolling)
• Rocky Mountain Regional VA Medical Center — Aurora, Colorado, United States (enrolling)
• Cardiology Associates of Fairfield County, P.C — Bridgeport, Connecticut, United States (enrolling)
• Hartford Hospital — Hartford, Connecticut, United States (enrolling)
• Yale New Haven Health Heart & Vascular Center Outpatient Services — New Haven, Connecticut, United States (enrolling)
• CHF Heart Clinical (Subject Visits & IP Shipments) — Clearwater, Florida, United States (enrolling)
• Holy Cross Medical Group - Cardiology Associates — Fort Lauderdale, Florida, United States (enrolling)
• South Florida Research Solutions, LLC — Hollywood, Florida, United States (enrolling)
• UF Health Jacksonville — Jacksonville, Florida, United States (enrolling)
• Broward Research Center — Miami Beach, Florida, United States (enrolling)
• Ocala Cardiovascular Research — Ocala, Florida, United States (enrolling)
• AdventHealth — Orlando, Florida, United States (enrolling)
• USF Health South Tampa Center for Advanced Healthcare — Tampa, Florida, United States (enrolling)
• Grady Health System — Atlanta, Georgia, United States (enrolling)
• Piedmont Atlanta Hospital — Atlanta, Georgia, United States (enrolling)
• Emory Clinic — Atlanta, Georgia, United States (enrolling)
• Piedmont Fayette Hospital — Fayetteville, Georgia, United States (enrolling)
• The Queen's Medical Center - Punchbowl — Honolulu, Hawaii, United States (enrolling)
• University of California, Irvine Medical Center — Orange, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.